Editpep develops CRISPR based therapeutics using a proprietary, programmable, peptide based delivery platform for targeted delivery to specific cell types. Progress: • In vivo data shows functional Cas9 enzyme delivery into the neurons of the striatum of mice, achieving 3X higher potency than that seen (published) with standard adeno-associated-virus (AAV) - based delivery • Data indicates that we can currently deliver CRISPR to cells in vivo to the brain and eye, and ex vivo to T cells and hematopoietic stem cells • Delivery technology is plug and play for a variety of different types of CRISPR enzymes with potential to target delivery to other organs Editpep's Transporter platform technology addresses a huge market need for more efficient CRISPR delivery to the brain and offers an easy to manufacture, highly efficient alternative to AAV or lipid nano particle (LNP) delivery of CRISPR to other target organs as well. Our lead clinical program is Dravet Syndrome, SAM $1.6B (US).